Ulcerative colitis is a chronic debilitating disease for which there is little effective therapy.
We have designed specific anti-colitic agents, and developing improved compounds. These compounds will control symptoms, but also block or slow down the process of the disease, and are targetted at the colon. In vivo efficacy has bee demonstrated in animal models. SIDR seeks an industrial partner to accelerate the project in exchange for commercial rights. For further information on this opportunity, please complete the electronic reply sheet .